PA
CNTA

Perceptive Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Perceptive Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209M Buy
5,258,903
+2,341,269
+80% +$59.9M 4.08% 5
2025
Q4 		$73M Sell
2,917,634
-183,268
-6% -$4.64M 1.3% 25
2025
Q3 		$75.2M Buy
3,100,902
+1,953,967
+170% +$34.7M 2.17% 15
2025
Q2 		$15.1M Sell
1,146,935
-1,893,460
-62% -$24M 0.56% 44
2025
Q1 		$43.7M Sell
3,040,395
-3,308,825
-52% -$54.1M 1.54% 16
2024
Q4 		$106M Buy
6,349,220
+66,930
+1% +$1.11M 2.93% 9
2024
Q3 		$100M Buy
6,282,290
+2,348,983
+60% +$28.8M 2.13% 12
2024
Q2 		$35.5M Buy
3,933,307
+850,000
+28% +$8.06M 0.86% 33
2024
Q1 		$34.8M Buy
+3,083,307
New +$29.2M 0.61% 51

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Perceptive Advisors's CNTA Position: Q1 2026 in Review

Perceptive Advisors increased its Centessa Pharmaceuticals (CNTA) stake by 80% in Q1 2026, buying an estimated $59.9M and bringing the position to 5,258,903 shares worth $209M. The position accounts for 4.08% of the portfolio, ranked #5.

Perceptive Advisors first reported a position in CNTA in Q1 2024 and has held it in 9 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Perceptive Advisors held 5,258,903 shares of Centessa Pharmaceuticals worth $209M as of Q1 2026.
  • Perceptive Advisors bought 2,341,269 Centessa Pharmaceuticals shares in Q1 2026, an estimated $59.9M.
  • Centessa Pharmaceuticals made up 4.08% of Perceptive Advisors's portfolio in Q1 2026, its #5 holding.
  • Perceptive Advisors first reported a position in Centessa Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.